Sildenafil Tablet, Film Coated
Product Images NDC 71205-220

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 71205-220). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (Sildenafil Fig1)

Figure 1 (Sildenafil Fig1)
The text provides a chart showing changes in sitting systolic blood pressure in healthy volunteers before and after taking 100mg of Sildenafil or a placebo. The readings were taken at different time points post-dose with the corresponding change from the baseline.*
FDA Label Image

71205-220-10 (Sildenafil Fig10)

71205-220-10 (Sildenafil Fig10)
This is a medication with the National Drug Code 71205-220-10 used to treat erectile dysfunction. It contains 10 tablets of sildenafil citrate USP, equivalent to 100 mg sildenafil. The tablets are diamond-shaped, white to off-white color and have a film coating. They are marked with 'T' on one side and '30' on the other side. The medication is manufactured by Aurobindo Pharma Limited in Hyderabad, India and packaged by Proficient Rx LP in Thousand Oaks, CA. It is advised to store the medication at a temperature ranging from 20°-25°C (68°-77°F) and should be kept out of reach of children. The Lot # is 00000 and the expiration date is 00/00/00. Also, there are multiple SN#MASTERs listed.*
FDA Label Image

Figure 2 (Sildenafil Fig2)

Figure 2 (Sildenafil Fig2)
This is a graph showing the change in systolic blood pressure (SBP) in mmHg over time postdose (in hours) for two different medication treatments - Doxazosin + Placebo and Doxasin + Sildenafil 25mg. The graph shows 5 data points with corresponding SBP values for each treatment. The mean standing SBP change from baseline is also displayed.*
FDA Label Image

Figure 3 (Sildenafil Fig3)

Figure 3 (Sildenafil Fig3)
The text appears to be a table/chart showing changes in mean standing systolic blood pressure from baseline for two groups taking either doxazosin and placebo or doxazosin and sildenafil 50 mg over time post-dose. The X-axis displays the time in hours and the Y-axis displays the mean standing systolic blood pressure change from the baseline. However, given the limited nature of the text provided, it is not possible to provide a full description.*
FDA Label Image

Figure 4 (Sildenafil Fig4)

Figure 4 (Sildenafil Fig4)
FDA Label Image

Figure 5 (Sildenafil Fig5)

Figure 5 (Sildenafil Fig5)
FDA Label Image

Figure 6. Effect Of Sildenafil And Placebo On Maintenance Of Erection By Baseline Score (Sildenafil Fig6)

Figure 6. Effect Of Sildenafil And Placebo On Maintenance Of Erection By Baseline Score (Sildenafil Fig6)
This is a figure depicting the effect of Sildenafil and Placebo on maintenance of erection based on baseline score. The figure shows the percentage of patients at endpoint in relation to their baseline scores. It indicates that Sildenafil has a better effect on maintenance of erection compared to placebo.*
FDA Label Image

Sildenafile Fig 7 (Sildenafil Fig7)

Sildenafile Fig 7 (Sildenafil Fig7)
FDA Label Image

Structure (Sildenafil Str)

Structure (Sildenafil Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.